Process Paper and Bibliography
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Polio Vaccine Safety Paul Meier's Role in the Discovery And
www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Downloaded from www.barkerstats.com/PDFs/Meier/Meier-Cutter-Incident-History.pdf Polio Vaccine Safety Paul Meier’s Role in the Discovery and Evaluation of The Cutter Incident Professor Chris Barker, Ph.D. Adjunct Associate Professor of Biostatistics, UIC SPH. www.barkerstats.com Page 1 of 11 www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Contents Background .................................................................................................................................................................................................................... 3 Brief Polio Vaccine Overview ......................................................................................................................................................................................... 3 Polio Vaccine Manufacturing Data Suppression ............................................................................................................................................................ 4 Biological Disaster? How Serious was the vaccine manufacturing problem? ............................................................................................................... 5 Near Elimination of Vaccine development by lawsuits ................................................................................................................................................. 6 Meier’s evaluation of the safety recommendations following The Cutter Incident .................................................................................................... -
1 X 60 It Was the Largest Public Health Experiment in Modern History— a Crusade That Eradicated One of the Twentieth Century’S Most Dreaded Diseases
1 x 60 It was the largest public health experiment in modern history— a crusade that eradicated one of the twentieth century’s most dreaded diseases. In the summer of 1950, fear gripped the residents of Wytheville, Virginia. Movie theaters shut down, baseball games were cancelled and panicky parents kept their children indoors—anything to keep them safe from an invisible invader. Outsiders sped through town with their windows rolled up and bandanas covering their faces. The ones who couldn’t escape the perpetrator were left paralyzed, and some died in the wake of the devas- tating and contagious virus. Polio had struck in Wytheville. The town was in the midst of a full-blown epidemic. That year alone, more than 33,000 1 x 60 Americans fell victim—half of them under the age of ten. The polio epidemic terrified Americans for decades, affecting thou- CONTACT sands of children, leaving many crippled, paralyzed, or condemned to life in Tom Koch, Vice President an iron lung. But on April 26, 1954, hope emerged. At the Franklin Sherman PBS International 10 Guest Street Elementary School in McLean, Virginia, six-year-old Randy Kerr stood at Boston, MA 02135 USA the head of a long line of children, and waited patiently while a nurse gently TEL: 617-300-3893 rolled up his sleeve, then filled a syringe with a cherry-colored liquid con- FAX: 617-779-7900 taining the world’s first polio vaccine. Developed just a few years earlier by [email protected] virologist Jonas Salk, the polio vaccine had not yet been widely tested on pbsinternational.org humans. -
Our Global Initiative
2021 OUR GLOBAL INITIATIVE AN ASSESSMENT OF COVID-19 & THE FAILED GLOBAL HEALTH POLICIES OF THE WHO OUR GLOBAL INITIATIVE In early 2020, Australia, and indeed the world, collapsed into a lockdown prompted by the World Health Organisation in its designation of Covid 19 as a pandemic. What began as “2 weeks to flatten the curve” quickly morphed into a year of intermittent lockdowns, a loss of freedoms and liberties, the decimations of SME’s, irrational restrictions, unadulterated government surveillance, an endless state of emergencies, the rise of the police state a totalitarian grand stride towards medical fascism and a technocratic dictatorship as well as the end of civil society as we know it. What happened? How did we get here? Where are we going? What does this world of the “New Normal” hold for not only Australia, but the human civilisation? How do we navigate this reality and not only survive but thrive? The Global Health Organisation, in collaboration with the Australian Patriots Alliance, the World Solutions Foundation, the QuantumPrism Foundation, Ikighais Pty Ltd and other concerned institutions (the Initiative) have commissioned this report in effort to gain an insight into what is going on; the why, they how and the WHO! Further, the report will offer solutions to current concerns, as well as ways for interested parties to position themselves to thrive and win in the new society bound to emerge from the ashes of this dying world. 2 TIPS TO HELP READ THIS REPORT This report contains a lot of information and we appreciate SUMMARY POINTS that time is scarce. -
Take Charge of Your Health Today. Be Informed. Be Involved. COVID-19 Vaccine Trials Must Include Black Community
A6 JULY 8-14, 2020 HEALTH NEW PITTSBURGH COURIER Take Charge Of Your Health Today. Be Informed. Be Involved. COVID-19 vaccine trials must include Black community This month, the “Take Charge of Your up 25% of all COVID-19 cases in Allegheny ment phase. African American participants Health Today” page discusses vaccine tri- County (according to the Allegheny County are then typically interacting with an all- als and their relationship with Pittsburgh’s Health Department), yet only make up about white research team. This could lead to lower African American community. The current 13% of its population. We can’t afford not to retention rates. Including African Americans COVID-19 pandemic has increased pres- be included in the COVID-19 vaccine clinical throughout the entire process looks like gar- sure for the medical community to develop trials. nering input around recruitment and reten- a vaccine to combat COVID-19. The devel- In order to gain footing in research-inclu- tion plans, protocols and the dissemination opment of a new vaccine means that clinical sive spaces, it is my hope that studies include process. trials will eventually begin to recruit par- opportunities for community input on topics Establish pipelines for researchers from ticipants. We must ensure that COVID-19 like the value of participation. What is in it for the community. African Americans are usu- clinical trials will include African American community members who are asked to share ally an afterthought when conducting re- participants. Systemic racism in the United their lived experiences? What is the plan for search studies. -
Chronological Introduction of Types of Vaccine Products That Are Still Licensed in the United States
Appendix 2.3 CHRONOLOGICAL INTRODUCTION OF TYPES OF VACCINE PRODUCTS THAT ARE STILL LICENSED IN THE UNITED STATES The year of introduction of each of 49 of the 51 shown in table 2.3B, American pharmaceutical com- types of vaccine prducts currently licensed in the panies were issued 37 (89 percent) of the original United States, alolng with the manufacturing estab- licenses for these 42 products. New or improved lishment with the oldest license still in effect for each types of products that are currently licensed have product, is shown in table 2.3 A.] For 42 (86 percent) been introduced at a fairly consistent rate of three to of these 49 products, the establishment that received seven products per each 5-year interval since 1940.2 the original product license still holds this license. As Ten of the currently licensed products were licensed before 1940. Table 2.3A—Chronological Introduction of Types of Vaccine Products Still Licensed in the United States Year Type of vaccine product Establishment with oldest product license still in effecta 1903 Dlphtherla antitoxin Massachusetts Public Health Biologic Laboratories (191 7) 1907 Tetanus antitoxin Parke. Davis and Company (191 5) 1914 Pertussis vaccine Lederle Laboratories Typhoid vaccine Massachusetts Public Health Biologic Laboratories (191 7) Rabies vaccine . Eli Lilly and Company* 1917 Cholera vaccine Eli Lilly and Company* 1926 Diphtheria toxoid Parke, Davis and Company (1927) 1933 Staphylococcus toxoid Lederle Laboratories* Tetanus toxoid Merck Sharp and Dohme 1941 Typhus vaccine Eli Lilly and Company 1942 Plague vaccine .., . Cutter Laboratories* Rocky Mountain Spotted Fever vaccine. Lederle Laboratories* 1945 InfIuenza virus vaccine Lederle Laboratories Merck Sharp and Dohme Parke, Davis and Company * 1946 Parke, Davis and Company ● 1947 Parke, Davis and Company (1949) 1948 Parke, Davis and Company (1952) Parke. -
Public Partnership Jonas Salk Research
THE UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH FALL 2012/WINTER 2013 The Legacy PUBLIC of and RESEARCH more PARTNERSHIP JONAS Highlights … SALK “It [was] a proud moment in the city and the region’s history. And it changed the course of biomedical science. The development of the polio vaccine is important to remember, because it became our Margaret McDonald, associate vice chancellor scientific future.” for academic affairs in the health sciences Pitt Public Health Magazine Fall 2012/Winter 2013 A publication of the Managing Editor: Sonia Gill For inquiries, feedback, or comments please contact: Writers: Christine O’Toole, Allison Hydzik, Sonia Gill, Director of External Affairs, Cyndy McGrath, Sonia Gill, Cathryn Hoel, [email protected] Karen Coulter Perkins, Kristen de Paor Pitt Public Health is published biannually for Marketing Communications Manager: the alumni and friends of the University of Karen C. Perkins A600 Crabtree Hall Pittsburgh Graduate School of Public Health. 130 DeSoto Street Design: Little Kelpie Pittsburgh, PA 15261 Pitt Public Health is printed on Roland Enviro Printing: Knepper Press, Migliozzi Printing 100 paper using vegetable-based inks. www.publichealth.pitt.edu Services Cover Image: Photography: Sam Hogson, R. Alan Adams, Frozen laboratory samples from the University of Pittsburgh Center for Cert no. XXX-XXX-000 pioneering poliomyelitis research Instructional Development and Distance conducted at Pitt by Jonas Salk; photographed by Jonathan Salk Education, Karen Coulter Perkins Dean’s MessaGE Collaborative Partnerships Inspiration for our work at Pitt Public Health comes from all over the that Pitt Public Health has the considerable talent to change world. I recently had the privilege of exploring the archives of Jonas those outcomes and an obligation to the community to demand Salk in California. -
The Academic Model for the Prevention and Treatment of HIV
C A S E S I N G L O B A L H E A L T H D ELIVERY GHD-045 JULY 2021 Building the Supply Chain for COVID-19 Vaccines Mid-April 2020 saw a rapid escalation of the COVID-19 pandemic. In the four months after December 2019, when the novel coronavirus that causes COVID-19 was first detected in Wuhan, China, the virus had infected several million people globally, with more than a hundred thousand confirmed deaths (see Exhibit 1 for daily confirmed deaths by country). China and Italy experienced major outbreaks early and saw hospitals flooded with COVID-19 patients, causing major shortages of vital intensive-care materials. To forestall the overburdening of health care resources, more than a dozen major countries imposed strict lockdowns to slow the spread of the disease, or “flatten the curve” (see Exhibit 2 for a map of government responses). Government lockdowns disrupted supply and demand in vital industries including retail, tourism, manufacturing, and services, crippling the global economy. As the massive scale of the crisis became apparent, financial markets began to collapse during February, leading some experts to warn of a potential next Great Depression and governments to announce unprecedented rescue packages to contain the destructive economic impact of the crisis. As governments navigated trade-offs between economic and public health outcomes, a global race had begun for the rapid discovery, production, and distribution of a safe and effective vaccine. The organization of supply chains to manufacture, distribute, and administer a vaccine to a sufficient portion of the 7.6 billion world population to contain the disease, a concept termed “herd immunity,” posed significant challenges. -
De Novo Synthesis and Secretion of a 36-Kd Protein by Cells That Form Lupus Inclusions in Response to Alpha-Interferon
De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon. S A Rich J Clin Invest. 1995;95(1):219-226. https://doi.org/10.1172/JCI117643. Research Article In response to the pure recombinant human alpha-IFN, IFLrA, Raji and Daudi were the only two cell lines among 19 human lymphoblastoid cell lines tested that formed the human lupus inclusions (LI) to a high frequency. Raji, Daudi, and five other cell lines were examined for protein changes that might accompany LI formation. Their selection was based upon T or B origin, association with Epstein-Barr virus, and ability to form LI. A trace protein of an estimated molecular mass of 36 kD (p36) and an isoelectric point of 5.6 was detected on two-dimensional gels only of alpha-IFN-treated Raji and Daudi cells. Gamma-IFN did not induce p36 or LI in any of these seven cell lines. In Daudi cells p36 and LI formed simultaneously in response to IFLrA, and persisted until the alpha-IFN-induced death of the culture. In Raji cells, p36 and LI appearance and disappearance coincided with the addition and removal of alpha-IFN. Fractionation of Raji cells with nonionic-detergent buffer placed p36 with the inclusions in the cytoplasmic supernatant. With detergent-free buffer p36 and LI were distributed evenly between the nuclear and cytoplasmic fractions. Pulse-chase experiments revealed that p36 was secreted. The de novo synthesis of p36 with alpha-IFN treatment was shown by labeling the cell proteins with [35S] methionine before and after the addition of alpha-IFN. -
Robert J. Desalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944
Robert J. DeSalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944 - 1990 Collection #107 Abstract Robert J. DeSalvo’s research focused on business combinations (acquisitions, mergers, and joint ventures in the cosmetic and pharmaceutical industries. This topic was the basis for his master’s thesis in pharmacy administration at the University of Pittsburgh and continued as a life-long interest. This collection consists of two series of notebooks that Dr. DeSalvo developed to record relevant business combinations. The first series records acquisitions, proposed acquisitions, mergers, and joint ventures for the period of 1944 –1990 in an alphabetical arrangement. The information on these entries is cumulative so that the history of an organization is collected in one place. The second series of notebooks is arranged in chronological blocks. The information is arranged alphabetically by the name of the acquirer. The name of the acquired (merged), type of combination (acquisition, proposed acquisition, joint venture) and the date is also provided. The information is cross-referenced between the two series so that the researcher can approach the information by the name of the parent company or chronologically. Dr. DeSalvo used this resource for many of his publications as well as his master’s thesis. A copy of these publications and his thesis make up the remainder of the collection. Donor Gift of Barbara DeSalvo, 2000 Biography Robert James DeSalvo was born on July 20, 1933 in Toledo, OH. He died on January 23, 1993 in Cincinnati, OH. DeSalvo graduated from high school in Toledo and attended pharmacy school at the University of Toledo where he received his B.S. -
[1] Vaccination Update Table of Contents: 1
EYE ON THE MARKET • MICHAEL CEMBALEST • J.P. MORGAN Last updated 9/23/2021 [1] Vaccination update Table of Contents: 1. US vaccination overview ................................................................................................................................2 2. Vaccination vs infection, mortality, hospitalization and 2020 Trump voting share ............................................3 3. “A pandemic of the unvaccinated” .................................................................................................................4 4. Population shares, vaccine efficacy and the amalgamation paradox ................................................................5 5. Vaccine efficacy tracker ..................................................................................................................................6 6. Vaccination vs previous COVID infection (acquired vs natural immunity) .........................................................7 7. Vaccine risk-benefit data ................................................................................................................................8 8. Variant prevalence by country ........................................................................................................................9 9. Delta variant facts and figures ........................................................................................................................9 10. Vaccine update by country and US state ...................................................................................................... -
A Message from Your President
Volume 21 No. 3 3rd. Quarter 2019 Polio News PRESENTED BY WILDROSE POLIO SUPPO R T S O C I E T Y INSIDE THIS ISSUE: A message from your Laughter Is Good P r e s i d e n t 2 Medicine Hello and welcome to the summer edition of POLIO NEWS. As your new Pres- ident, let me introduce myself. My name is John Sugden. My wife, Marge, and Next Event 3 I, have been members of the Society for 5 years. Marge is the Polio Survivor and has Post Polio Syndrome. Prior to moving to St. Albert, we lived in Chilli- A Great Lesson On wack, BC, Cold Lake and Calgary. While in BC we were members of PPASS 4 Stress BC (Post Polio Awareness and Support Society). You are probably aware of two events coming up with WPSS, but let me remind Julius Youngner, Polio 5 you. Vaccine Pioneer First, our annual picnic is scheduled for August 9th at Hawrelak Park. It’s a 20th Anniversary Cele- 6 good time to socialize and have some munchies with folks we don’t see very of- bration ten throughout the year. Wanted— th th 7 Second, the event of the year happens on September 28 – the 20 Anniversary an Administrator of the Society. I hope you will consider attending; plus, talk to friends and rela- tives who might also like to celebrate with us. We are planning to have enter- tainment, guest speakers and a fine meal. There will be a silent auction of items Pictures from the AGM 8 you ‘just need to take home!’, and the book about our polio journeys will be available. -
Julius Youngner 1920–2017
OBITUARY Julius Youngner 1920–2017 UPMC/Pitt Health Sciences Vincent Racaniello Without Julius Youngner, the world would not be on the verge of with the idea of using cell cultures to study viruses, an interest that eradicating poliomyelitis. It is true that Jonas Salk and Albert Sabin lead him to Pittsburgh to work with Salk on an inactivated vaccine developed the vaccines against poliovirus. However, behind every against poliovirus. great scientific achievement are those who made it possible. The efficacy of Salk’s vaccine against poliovirus was tested in a phase Salk was working on developing the inactivated vaccine against III clinical trial in 1954, the largest ever done, involving 1.8 million poliovirus when he heard that a young scientist was looking for ways children. Within months after licensure of the vaccine in April 1955, to use cell culture to study viruses. Youngner had worked on cell cul- children began to develop paralysis that was traced to batches of incom- ture at the National Institutes of Health and wanted to combine his pletely inactivated vaccine produced by Cutter Laboratories. Youngner knowledge with the study of virology. After receiving Salk’s invitation, recalled that he had traveled to the company early in April 1955 and he arrived at the University of Pittsburgh in 1949. found that scientists there were having difficulty with the procedure Salk’s group had been using monkeys to conduct neutralization for inactivating the virus with formalin. He told Salk that the company assays to determine the number of poliovirus serotypes. Youngner should not be permitted to make the vaccine.